
Illumina (ILMN) Stock Forecast & Price Target
Illumina (ILMN) Analyst Ratings
Bulls say
Illumina is positioned for growth in the life science and clinical lab markets through its high-throughput sequencing technology and low throughput tools for smaller data output applications. The company has a strong track record of beating revenue and earnings expectations and raises guidance accordingly. As clinical adoption of their on-market tests expands, Illumina expects sustained revenue growth and is taking proactive measures to optimize their cost structure. While there are headwinds from China, tariffs, and the research market, Illumina's strong hold on the clinical sequencing market and potential growth opportunities in early detection and MRD make it a promising investment.
Bears say
Illumina is experiencing strong momentum in its instruments segment, partly driven by end-market demand in clinical customers and continued lab investment for future tests. Despite some discounting, the company did not update their expectations for quarterly X placements, and they expect more demand than supply for their instruments. Additionally, Illumina is focused on capturing longer-term business, rather than offering lower list prices in the near term. However, there are concerns over future policy changes which may pause any new projects in sequencing, and both the academic and pharma markets are showing limited growth potential for the company.
This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.
Illumina (ILMN) Analyst Forecast & Price Prediction
Start investing in Illumina (ILMN)
Order type
Buy in
Order amount
Est. shares
0 shares